Colchicina, perspectivas de un viejo amigo para la reumatología en la COVID-19: una revisión exploratoria

Tuta-Quintero, Eduardo; Vega-Corredor, María Camila; Perdomo-Rodríguez, Laura Sofía; Pimentel, Juan

doi:10.1016/j.rcreu.2021.02.002

Cited by 5 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, antiviral (lopinavir and interferon) and non-antiviral (colchicine) treatments do not positively impact mortality, mechanical ventilation requirements, or length of hospital stay [61][62][63] ; only remdesivir has shown clinical improvement in hospitalized adults with severe COVID-19 symptoms 64 . However, its use is limited in the pediatric population with clinical manifestations of MIS-C because the clinical picture presented in the acute phase of the disease is associated with undetectable viral loads by RT-PCR 35 .…”

Section: Discussionmentioning

confidence: 99%

Multisystem inflammatory syndrome and COVID-19: a scoping review

Tuta-Quintero¹,

Martínez-Ayala²,

Mantilla-Beltrán³

et al. 2022

BMHIM

Self Cite

View full text Add to dashboard Cite

Background: Multisystem inflammatory syndrome temporally associated with COVID-19 presents with similar symptomatology and therapeutic approach to Kawasaki disease in the pediatric population. Given the novelty of the disease and the growing scientific literature on the subject, it is relevant to collect and report available scientific information. This review aimed to explore the medical evidence on multisystem inflammatory syndrome temporally associated with COVID-19 in a population under 18 years of age. Methods: We conducted a scoping review using Scopus and PubMed, including observational (cohort, case-control, and cross-sectional) studies and case series. Results: Of the total articles reviewed as of April 10, 2021, 45 articles met eligibility criteria: case series (n = 32), retrospective cohort studies (n = 6), prospective cohort studies (n = 4), case-control studies (n = 2), and cross-sectional studies (n = 1). Gastrointestinal and respiratory symptoms and myocardial dysfunction are the most commonly reported. The most relevant paraclinical markers were lymphopenia, thrombocytopenia, and elevated D-dimer levels. Conclusions: The multisystem inflammatory syndrome temporally associated with COVID-19 presents a broad spectrum of signs and symptoms. Aneurysms of the coronary arteries and myocarditis are usually present in the acute phases of the disease. The early diagnosis led by a multidisciplinary group of pediatric intensivists, infectious disease specialists, cardiologists, and rheumatologists allows adequate and effective medical management.

show abstract

Section: Discussionmentioning

confidence: 99%

Multisystem inflammatory syndrome and COVID-19: a scoping review

Tuta-Quintero¹,

Martínez-Ayala²,

Mantilla-Beltrán³

et al. 2022

BMHIM

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are therefore sufficient reasons for studying colchicine as a possible treatment for COVID‐19. 7 , 14 …”

Section: Introductionmentioning

confidence: 99%

“…There are therefore sufficient reasons for studying colchicine as a possible treatment for COVID-19. 7,14 To date, the available evidence points to colchicine's role in preventing progression from an inflammatory activation stage to a hyperinflammatory stage, characteristic of patients in moderate-tosevere stages of the disease (stages II and III). [15][16][17][18][19][20][21][22][23] Even so, few studies envisage it being used as prophylaxis 24 or on nonhospitalised patients.…”

Section: Introductionmentioning

confidence: 99%

Colchicine and risk of hospitalization due to COVID‐19: A population‐based study

Aldea

Salgado‐Barreira

Trunk

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Colchicine is one of the most widely studied and best‐known anti‐inflammatory treatments. This study aimed to assess the effect of colchicine on risk of hospitalization due to COVID‐19; and its effect on susceptibility to and severity of the virus in patients with COVID‐19. We carried out a population‐based case‐control study. The following groups were applied: (1) to assess risk of hospitalization, cases were patients with a positive PCR who were hospitalized due to COVID‐19, and controls without a positive PCR; (2) to assess susceptibility to COVID‐19, cases were patients with a positive PCR (hospitalized and non‐hospitalized), and the same controls; (3) to determine potential severity, cases were subjects with COVID‐19 hospitalized, and controls patients with COVID‐19 nonhospitalised. Different electronic, linked, administrative health and clinical databases were used to extract data on sociodemographic variables, comorbidities, and medications dispensed. The study covered 3060 subjects with a positive PCR who were hospitalized, 26 757 with a positive PCR who were not hospitalized, and 56 785 healthy controls. After adjustment for sociodemographic variables, comorbidities and other treatments, colchicine did not modify risk of hospitalization due to COVID‐19 (adjusted odd ratio [OR] 1.08 [95% confidence interval (CI) 0.76−1.53]), patients' susceptibility to contracting the disease (adjusted OR 1.12 (95% CI 0.91−1.37)) or the severity of the infection (adjusted OR 1.03 [95% CI 0.67−1.59]). Our results would neither support the prophylactic use of colchicine for prevention of the infection or hospitalization in any type of patient, nor justify the withdrawal of colchicine treatment due to a higher risk of contracting COVID‐19.

show abstract

“…A finales del año 2019 la infección por el síndrome respiratorio agudo severo coronavirus tipo 2 (SARS-CoV-2) surgió en la ciudad de Wuhan, China, responsable de la actual pandemia por la enfermedad por coronavirus 2019 (COVID-19) 1 . Los principales signos y síntomas son fiebre, tos y dolor torácico, y en menor porcentaje disnea, síndrome de dificultad respiratoria aguda y falla multiorgánica 2 , más severa en adultos con múltiples comorbilidades en comparación con la población pediátrica 3 .…”

Section: Introductionunclassified